DEERFIELD, Ill.—Baxter International will acquire for $380 million Baxa Corporation, which focuses on technology in oral and IV dose preparation and delivery.
Baxter said the addition will complement its portfolio of nutrition products and drug delivery systems and supports patient safety. Baxa is based in Englewood, Colo., and has additional operations in Florida and the United Kingdom.
"With these new offerings, Baxter will be able to provide a comprehensive solution to fulfill the majority of patients' nutritional requirements and increase efficiency in the pharmacy," said Robert M. Davis, president of Baxter's Medical Products business. "Bringing this expertise together with Baxter's commercial capabilities and global reach will enable us to continue to meet our customers' evolving needs and extend our position in IV nutrition and fluid delivery."
Baxa’s annual sales were approximately $150 million in 2010, and Baxter expects the future top-line growth of this business to be accretive to the company's future sales growth. In addition, Baxter expects this transaction to be neutral to full-year 2012 earnings excluding dilution of approximately $0.03 to $0.05 per diluted share related to acquisition accounting and transaction-related expenses, and increasingly accretive thereafter.